Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two drugs as a possible treatment for
Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The interventions involved in this study are:
- Osimertinib (Tagrisso)
- Gefitinib (Iressa)